Moleculin Biotech Inc reports results for the quarter ended in January - Earnings Summary

Moleculin Biotech

10/05/2024 23:26

* Moleculin Biotech Inc  MBRX.OQ  reported a quarterly
adjusted
loss of $2.02​​ per share for the quarter ended in January,
higher than the same quarter last year, when the company
reported EPS of $-4.20.  The mean expectation of two analysts
for the quarter was for a loss of $3.53 per share. Wall Street
expected results to range from $-3.59 to $-3.47 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Moleculin Biotech Inc's reported EPS for the quarter was a
loss
of $2.02​.
    * The company reported a quarterly loss of $4.97 million.
    * Moleculin Biotech Inc shares had fallen by 19.1% this
quarter and lost 62.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 47.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Moleculin Biotech
Inc is $40.00 
This summary was machine generated from LSEG data May 10 at
10:25 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -3.53          -2.02          Beat
 Dec. 31 2023      -3.05          -5.02          Missed
 Sep. 30 2023      -3.55          -2.85          Beat
 Jun. 30 2023      -4.10          -3.00          Beat